Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 11, 2002
- CDFS's Panel on Medical Devices to Prepare for New PAL Enforcement
November 11, 2002
- Ajinomoto Takes Over Shimizu Pharm
November 11, 2002
- JPA to Conduct Studies on Medical Benefits of Bungyo
November 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 11, 2002
- Tanabe Shifts to Independent Global Marketing
November 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 11, 2002
- Korosho to Standardize Definition, Duties of SMOs
November 11, 2002
- PI Forum Member Companies Maintain Interest in Drug Business
November 11, 2002
- TV Programs Should Be More Careful in Handling Healthcare Issues: Yamanouchi, Pfizer Seminar
November 11, 2002
- Roche Diagnostics: Accu-chek Compact Blood Glucose Meter
November 11, 2002
- FPMAJ Compiles Measures to Prevent Medical Accidents
November 11, 2002
- Life Science Summit Calls For Promotion of World's Leading R&D
November 11, 2002
- WORLD NEW IN BRIEF
November 11, 2002
- WEBSITE NEWS
November 11, 2002
- Researcher-led Clinical Trials on Anticancer Agents by NPO Introduced
November 11, 2002
- BUSINESS NEWS IN BRIEF
November 11, 2002
- CRCs Should Report All Events: SMO Seminar
November 11, 2002
- Fujisawa: Record-high Sales, Profits in 1st Half of FY2002 Marked
November 11, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 11, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…